{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:46:35Z","timestamp":1782873995097,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["VBD\/NIMR\/Intra\/0012\/CD-II"],"award-info":[{"award-number":["VBD\/NIMR\/Intra\/0012\/CD-II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-026-05912-1","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:26:15Z","timestamp":1778167575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protocol for a multicentric open-label randomized controlled trial comparing low-dose (0.25\u00a0mg\/kg) and standard-dose (0.75\u00a0mg\/kg) primaquine for gametocytocidal efficacy and safety in Plasmodium falciparum malaria"],"prefix":"10.1186","volume":"25","author":[{"given":"Payal","family":"Gulati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorv","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anjali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Kumar","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamond Prakash","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khileshwar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra Kumar","family":"Baharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. N.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashvin H.","family":"Vasava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Gamit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj B.","family":"Patki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem A.","family":"Malla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Kori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Savargaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nibir","family":"Chakma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daksh","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenin","family":"Alagesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritika","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup R.","family":"Anvikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen K.","family":"Bharti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitika","family":"Nitika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"31","key":"5912_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000043762","volume":"104","author":"EI Obeagu","year":"2025","unstructured":"Obeagu EI, Obeagu GU, Iduh MU. Behavioral health interventions in malaria control: efficacy and implementation. Medicine (Baltimore). 2025;104(31):e43762.","journal-title":"Medicine (Baltimore)"},{"key":"5912_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-025-03967-5","author":"S Nema","year":"2025","unstructured":"Nema S, Singhal R, Bharti PK, Nitika N. Malaria in pregnancy and its potential impact on neurodevelopment in children: a systematic review. Pediatr Res. 2025. https:\/\/doi.org\/10.1038\/s41390-025-03967-5.","journal-title":"Pediatr Res"},{"key":"5912_CR3","unstructured":"Venkatesan P. WHO world malaria report 2024. The Lancet Microbe. 2025;6(4)."},{"issue":"8","key":"5912_CR4","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1086\/503051","volume":"193","author":"JT Bousema","year":"2006","unstructured":"Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, et al. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis. 2006;193(8):1151\u20139.","journal-title":"J Infect Dis"},{"issue":"8","key":"5912_CR5","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/319689","volume":"183","author":"G Targett","year":"2001","unstructured":"Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, Deen J, et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis. 2001;183(8):1254\u20139.","journal-title":"J Infect Dis"},{"issue":"1","key":"5912_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-3156.2003.01169.x","volume":"9","author":"CJ Drakeley","year":"2004","unstructured":"Drakeley CJ, Jawara M, Targett GAT, Walraven G, Obisike U, Coleman R, et al. Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. Trop Med Int Heal. 2004;9(1):53\u201361.","journal-title":"Trop Med Int Heal"},{"issue":"4","key":"5912_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijpara.2006.01.002","volume":"36","author":"P Schneider","year":"2006","unstructured":"Schneider P, Bousema T, Omar S, Gouagna L, Sawa P, Schallig H, et al. (Sub) microscopic Plasmodium falciparum gametocytaemia in Kenyan children after treatment with sulphadoxine-pyrimethamine monotherapy or in combination with artesunate. Int J Parasitol. 2006;36(4):403\u20138.","journal-title":"Int J Parasitol"},{"issue":"1","key":"5912_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/1475-2875-7-237","volume":"7","author":"PF Mens","year":"2008","unstructured":"Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, Schallig HDFH, et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J. 2008;7(1):237.","journal-title":"Malar J"},{"issue":"11","key":"5912_CR9","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/infdis\/jit077","volume":"207","author":"P Sawa","year":"2013","unstructured":"Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY, et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis. 2013;207(11):1637\u201345.","journal-title":"J Infect Dis"},{"key":"5912_CR10","unstructured":"Arnold J, Alving AS, Hockwald ES, Clayman CB, Dern RJ, Bbutler E, et al. The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, PF-6 strain). 1955."},{"issue":"10","key":"5912_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001023","volume":"2","author":"S Shekalaghe","year":"2007","unstructured":"Shekalaghe S, Drakeley C, Gosling R, Ndaro A, Van Meegeren M, Enevold A, et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS ONE. 2007;2(10):e1023.","journal-title":"PLoS ONE"},{"issue":"5","key":"5912_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/cid\/cis959","volume":"56","author":"I Sutanto","year":"2013","unstructured":"Sutanto I, Suprijanto S, Kosasih A, Dahlan MS, Syafruddin D, Kusriastuti R, et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South Sumatra, Western Indonesia: an open-label, randomized, controlled trial. Clin Infect Dis. 2013;56(5):685\u201393.","journal-title":"Clin Infect Dis"},{"issue":"09","key":"5912_CR13","first-page":"709","volume":"107","author":"PQ Chen","year":"1994","unstructured":"Chen PQ, Li GQ, Guo XB, He KR, Fu YX, Fu LC, et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chin Med J (Engl). 1994;107(09):709\u201311.","journal-title":"Chin Med J (Engl)"},{"key":"5912_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.011","volume":"161","author":"SR Marcsisin","year":"2016","unstructured":"Marcsisin SR, Reichard G, Pybus BS. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: current state of the art. Pharmacol Ther. 2016;161:1\u201310.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"5912_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/QCO.0b013e328010b848","volume":"19","author":"BL Tekwani","year":"2006","unstructured":"Tekwani BL, Walker LA. 8-Aminoquinolines: future role as antiprotozoal drugs. Curr Opin Infect Dis. 2006;19(6):623\u201331.","journal-title":"Curr Opin Infect Dis"},{"key":"5912_CR16","volume-title":"New WHO guidelines for the treatment of malaria","author":"H Reyburn","year":"2010","unstructured":"Reyburn H. New WHO guidelines for the treatment of malaria, vol. 340. Bmj: British Medical Journal Publishing Group; 2010."},{"issue":"10","key":"5912_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1473-3099(10)70187-0","volume":"10","author":"F Smithuis","year":"2010","unstructured":"Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo APP, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis. 2010;10(10):673\u201381.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"5912_CR18","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1093\/ckj\/sfac154","volume":"15","author":"BM Beker","year":"2022","unstructured":"Beker BM, Colombo I, Gonzalez-Torres H, Musso CG. Decreasing microbiota-derived uremic toxins to improve CKD outcomes. Clin Kidney J. 2022;15(12):2214\u20139.","journal-title":"Clin Kidney J"},{"issue":"2","key":"5912_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.7705\/biomedica.v29i2.32","volume":"29","author":"AM V\u00e1squez","year":"2009","unstructured":"V\u00e1squez AM, San\u00edn F, \u00c1lvarez LG, Tob\u00f3n A, R\u00edos A, Blair S. Therapeutic efficacy of a regimen of artesunate-mefloquine-primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development. Biomedica. 2009;29(2):307\u201319.","journal-title":"Biomedica"},{"issue":"12","key":"5912_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001311","volume":"2","author":"B El-Sayed","year":"2007","unstructured":"El-Sayed B, El-Zaki SE, Babiker H, Gadalla N, Ageep T, Mansour F, et al. A randomized open-label trial of artesunate-sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS ONE. 2007;2(12):e1311.","journal-title":"PLoS ONE"},{"issue":"2","key":"5912_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1365-3156.2003.01180.x","volume":"9","author":"PT Giao","year":"2004","unstructured":"Giao PT, de Vries PJ, Hung LQ, Binh TQ, Nam NV, Kager PA. CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone\u2013proguanil against falciparum malaria in Vietnam. Trop Med Int Heal. 2004;9(2):209\u201316.","journal-title":"Trop Med Int Heal"},{"issue":"5","key":"5912_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1179\/000349804225003550","volume":"98","author":"KD Kamtekar","year":"2004","unstructured":"Kamtekar KD, Gogtay NJ, Dalvi SS, Karnad DR, Chogle AR, Aigal U, et al. A prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Ann Trop Med Parasitol. 2004;98(5):453\u20138.","journal-title":"Ann Trop Med Parasitol"},{"issue":"5","key":"5912_CR23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.4269\/ajtmh.2003.68.620","volume":"68","author":"Y Suputtamongkol","year":"2003","unstructured":"Suputtamongkol Y, Chindarat S, Silpasakorn S, Chaikachonpatd S, Lim K, Chanthapakajee K, et al. The efficacy of combined mefloquine-artesunate versus mefloquine-primaquine on subsequent development of Plasmodium falciparum gametocytemia. Am J Trop Med Hyg. 2003;68(5):620\u20133.","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"5912_CR24","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1128\/AAC.01135-09","volume":"54","author":"SA Shekalaghe","year":"2010","unstructured":"Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A\u2212) individuals. Antimicrob Agents Chemother. 2010;54(5):1762\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"5912_CR25","unstructured":"Reeve PA, Toaliu H, Kaneko A, Hall JJ, Ganczakowski M. Acute intravascular haemolysis in Vanuatu following a single dose of primaquine in individuals with glucose-6-phosphate-dehydrogenase deficiency. 1992."},{"key":"5912_CR26","unstructured":"Organization WH. The safety and effectiveness of single dose primaquine as a P. falciparum gametocytocide. WHO Evid Rev Group Geneva WHO. 2012."},{"issue":"1","key":"5912_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/1475-2875-11-424","volume":"11","author":"Secretariat WHOMPAC and","year":"2012","unstructured":"Secretariat WHOMPAC and. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. Malar J. 2012;11(1):424.","journal-title":"Malar J"},{"issue":"4","key":"5912_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006230","volume":"12","author":"J Recht","year":"2018","unstructured":"Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis. 2018;12(4):e0006230.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"5912_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-3121-3","volume":"19","author":"S Shekalaghe","year":"2020","unstructured":"Shekalaghe S, Mosha D, Hamad A, Mbaga TA, Mihayo M, Bousema T, et al. Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether\u2013lumefantrine. Malar J. 2020;19(1):34.","journal-title":"Malar J"},{"issue":"10491","key":"5912_CR30","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S0140-6736(25)00770-6","volume":"405","author":"AW Chan","year":"2025","unstructured":"Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, et al. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. Lancet. 2025;405(10491):e19-27.","journal-title":"Lancet"},{"issue":"10489","key":"5912_CR31","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/S0140-6736(25)00672-5","volume":"405","author":"S Hopewell","year":"2025","unstructured":"Hopewell S, Chan AW, Collins GS, Hr\u00f3bjartsson A, Moher D, Schulz KF, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. Lancet. 2025;405(10489):1633\u201340.","journal-title":"Lancet"},{"issue":"1","key":"5912_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.molbiopara.2004.03.018","volume":"137","author":"P Schneider","year":"2004","unstructured":"Schneider P, Schoone G, Schallig H, Verhage D, Telgt D, Eling W, et al. Quantification of Plasmodium falciparum gametocytes in differential stages of development by quantitative nucleic acid sequence-based amplification. Mol Biochem Parasitol. 2004;137(1):35\u201341.","journal-title":"Mol Biochem Parasitol"},{"issue":"3","key":"5912_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-002759","volume":"3","author":"AC Eziefula","year":"2013","unstructured":"Eziefula AC, Staedke SG, Yeung S, Webb E, Kamya M, White NJ, et al. Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open. 2013;3(3):e002759.","journal-title":"BMJ Open"},{"issue":"6","key":"5912_CR34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4097\/kja.23278","volume":"76","author":"E Ahn","year":"2023","unstructured":"Ahn E, Kang H. Intention-to-treat versus as-treated versus per-protocol approaches to analysis. Korean J Anesthesiol. 2023;76(6):531\u20139.","journal-title":"Korean J Anesthesiol"},{"issue":"3","key":"5912_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1046\/j.1365-2125.2001.01397-3.x","volume":"52","author":"CPMP C for PMP","year":"2001","unstructured":"CPMP C for PMP. Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol. 2001;52(3):223.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"5912_CR36","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2125.1985.tb02709.x","volume":"19","author":"GW Mihaly","year":"1985","unstructured":"Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol. 1985;19(6):745\u201350.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"5912_CR37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S1473-3099(13)70268-8","volume":"14","author":"AC Eziefula","year":"2014","unstructured":"Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis. 2014;14(2):130\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"5912_CR38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S1473-3099(22)00658-2","volume":"23","author":"WR Taylor","year":"2023","unstructured":"Taylor WR, Olupot-Olupot P, Onyamboko MA, Peerawaranun P, Weere W, Namayanja C, et al. Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, n. Lancet Infect Dis. 2023;23(4):471\u201383.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"5912_CR39","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12879-019-3862-1","volume":"19","author":"L Dysoley","year":"2019","unstructured":"Dysoley L, Kim S, Lopes S, Khim N, Bjorges S, Top S, et al. The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians. BMC Infect Dis. 2019;19(1):250.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"5912_CR40","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1128\/AAC.48.4.1329-1334.2004","volume":"48","author":"S Pukrittayakamee","year":"2004","unstructured":"Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ. Activities of artesunate and primaquine against asexual-and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother. 2004;48(4):1329\u201334.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"5912_CR41","first-page":"408","volume":"11","author":"Y Chomcharn","year":"1980","unstructured":"Chomcharn Y, Surathin K, Bunnag D, Sucharit S, Harinasuta T. Effect of a single dose of primaquine on a Thai strain of Plasmodium falciparum. Southeast Asian J Trop Med Public Health. 1980;11(3):408\u201312.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"5912_CR42","unstructured":"Kaneko A, Kamei K, Suzuki T, Ishii A, Siagian R, Panjaitan W. Gametocytocidal effect of primaquine in a chemotherapeutic malaria control trial in North Sumatra, Indonesia. 1989."},{"issue":"3","key":"5912_CR43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/0035-9203(54)90067-X","volume":"48","author":"RC Muirhead-Thomson","year":"1954","unstructured":"Muirhead-Thomson RC. Factors determining the true reservoir of infection of Plasmodium falciparum and Wuchereria bancrofti in a West African village. Trans R Soc Trop Med Hyg. 1954;48(3):208\u201325.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"5912_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijpara.2004.10.014","volume":"35","author":"E Nassir","year":"2005","unstructured":"Nassir E, Abdel-Muhsin AMA, Suliaman S, Kenyon F, Kheir A, Geha H, et al. Impact of genetic complexity on longevity and gametocytogenesis of Plasmodium falciparum during the dry and transmission-free season of eastern Sudan. Int J Parasitol. 2005;35(1):49\u201355.","journal-title":"Int J Parasitol"},{"issue":"12","key":"5912_CR45","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1086\/340638","volume":"185","author":"A Abdel-Wahab","year":"2002","unstructured":"Abdel-Wahab A, Abdel-Muhsin AMA, Ali E, Suleiman S, Ahmed S, Walliker D, et al. Dynamics of gametocytes among Plasmodium falciparum clones in natural infections in an area of highly seasonal transmission. J Infect Dis. 2002;185(12):1838\u201342.","journal-title":"J Infect Dis"},{"issue":"5","key":"5912_CR46","doi-asserted-by":"publisher","first-page":"700","DOI":"10.4269\/ajtmh.1993.48.700","volume":"48","author":"C Boudin","year":"1993","unstructured":"Boudin C, Olivier M, Molez JF, Chiron JP, Ambroise-Thomas P. High human malarial infectivity to laboratory-bred Anopheles gambiae in a village in Burkina Faso. Am J Trop Med Hyg. 1993;48(5):700\u20136.","journal-title":"Am J Trop Med Hyg"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-05912-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05912-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05912-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:25:55Z","timestamp":1782872755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-05912-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5912"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-05912-1","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Indian Council of Medical Research- National Institute of Malaria Research (ICMR-NIMR) Institutional Ethics Committee (IEC) has provided the approval for the study (NIMR\/IEC-M\/2023\/970\/v6-Jun\/01). In addition, the approval has also been sought for other four study sites . This clinical trial study has received ethical approval from the IEC\u2013Zoram Medical College and Hospital Mizoram; IEC\u2013Late Baliram Kashyap Medical College, Chhattisgarh; IEC\u2013RIMS, Ranchi, Jharkhand; Human Research Ethics Committee, Government Medical College, Surat, Gujarat. The trial is registered with Clinical Trial Registry of India (CTRI) with CTRI Registration details: CTRI\/2025\/07\/091988. Written informed consent is taken from all the participants who are willing to voluntarily adhere to the trial protocol and to be a part of the study for 28\u00a0days follow up period. Those who are not willing to provide the consent are referred to hospital and given treatment as per National treatment guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"251"}}